Cargando…

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

Medulloblastoma (MB) is the most common malignant brain tumor in children. MYC genes are frequently amplified and correlate with poor prognosis in MB. BET bromodomains recognize acetylated lysine residues and often promote and maintain MYC transcription. Certain cyclin-dependent kinases (CDKs) are f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolin, Sara, Borgenvik, Anna, Persson, Camilla U., Sundström, Anders, Qi, Jun, Bradner, James E., Weiss, William A., Cho, Yoon-Jae, Weishaupt, Holger, Swartling, Fredrik J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966365/ https://www.ncbi.nlm.nih.gov/pubmed/29511348 http://dx.doi.org/10.1038/s41388-018-0135-1

Ejemplares similares

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
por: Bandopadhayay, Pratiti, et al.
Publicado: (2019)

MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
por: Bolin, Sara, et al.
Publicado: (2020)

EMBR-07. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA BY ARF PATHWAY SUPPRESSION
por: Mainwaring, Oliver, et al.
Publicado: (2021)

MEDB-55. Single-cell transcriptomics reveals progenitor cells expressing a photoreceptor program as putative cells origin of MYC-driven Group 3 Medulloblastoma
por: Zhao, Miao, et al.
Publicado: (2022)

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
por: Borgenvik, Anna, et al.
Publicado: (2022)

Modeling and Targeting MYC Genes in Childhood Brain Tumors
por: Hutter, Sonja, et al.
Publicado: (2017)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes
por: Weishaupt, Holger, et al.
Publicado: (2019)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
por: Mainwaring, Oliver J., et al.
Publicado: (2023)

Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma
por: Liu, Xiaohua, et al.
Publicado: (2021)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Kandela, Irawati, et al.
Publicado: (2015)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2017)

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells
por: Čančer, Matko, et al.
Publicado: (2019)

MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
por: Kling, Matthew J., et al.
Publicado: (2022)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2018)

P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA
por: Oh, Danielle H., et al.
Publicado: (2023)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy
por: Čančer, Matko, et al.
Publicado: (2019)

Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells
por: Susanto, Evelyn, et al.
Publicado: (2020)

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma
por: Suryo Rahmanto, Aldwin, et al.
Publicado: (2016)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
por: Coleman, Daniel J., et al.
Publicado: (2019)

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
por: Shu, Shaokun, et al.
Publicado: (2016)

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
por: Devaraj, Santhana G. T., et al.
Publicado: (2015)

Mouse medulloblastoma driven by CRISPR activation of cellular Myc
por: Vo, BaoHan T., et al.
Publicado: (2018)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Nuclear Receptor Binding Protein 2 Is Downregulated in Medulloblastoma, and Reduces Tumor Cell Survival upon Overexpression
por: Xiong, Anqi, et al.
Publicado: (2020)

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
por: Tang, Yujie, et al.
Publicado: (2014)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_43m0dv653krmnjnt2f6ht7elk5